Cendakimab Biosimilar - Research Grade

Human

IL13

>1mg/ml

IgG1 - kappa

CHO Cells

Lebrikizumab Biosimilar - Research Grade (ICH5058), Tralokinumab Biosimilar - Research Grade (ICH5059), Abrezekimab Biosimilar - Research Grade (ICH5324), Anrukinzumab Biosimilar - Research Grade (ICH5347), Dectrekumab Biosimilar - Research Grade (ICH5470), Riltovetbart Biosimilar - Research Grade (ICH5822)

https://www.imgt.org/mAb-DB/

ICH3002

P35225

Blue ice

This product is a research-grade biosimilar of cendakimab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is not the clinical drug and is not intended for diagnostic or therapeutic use. Cendakimab is a humanized IgG1 kappa monoclonal antibody directed against human interleukin-13 (IL-13); this analog is built around that same target specificity, reproducing binding to human IL-13 so investigators can study the ligand-blocking pathway in controlled settings. The originator has been developed clinically for eosinophilic esophagitis and other type 2 inflammatory conditions, where IL-13 is a central driver. As a research reagent, the biosimilar is intended to support functional and in-vitro applications rather than treatment: ligand-binding characterization, neutralization assays, receptor-interaction studies, assay development, and as a comparator or positive control alongside other anti-IL-13 tools. It is produced to in-vivo research standards with low endotoxin and is available in bulk quantities. Because it targets a human cytokine, its principal value is in human-system and biochemical work rather than routine mouse in-vivo dosing. Interleukin-13 (IL-13; UniProt P35225) is a type 2 (Th2) cytokine central to allergic and fibrotic inflammation. It is produced chiefly by activated Th2 cells, mast cells, basophils, and group 2 innate lymphoid cells. IL-13 signals through a receptor system it shares partly with IL-4: it binds IL-13 receptor alpha 1 (IL13RA1), which pairs with the IL-4 receptor alpha chain to form the type II receptor and activate STAT6, and it also binds the high-affinity decoy receptor IL-13 receptor alpha 2 (IL13RA2). Downstream effects include IgE class switching, goblet cell hyperplasia, mucus production, smooth muscle changes, eosinophil recruitment via chemokines such as CCL26/eotaxin-3, and tissue remodeling. IL-13 is a key driver of eosinophilic esophagitis, asthma, atopic dermatitis, and related type 2 diseases, which makes ligand-neutralizing antibodies a focus of both therapeutic development and mechanistic research.

Interleukin-13, NC30

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks